Disease Areas

Our world-class neurology research and development organization is pushing toward novel approaches for previously intractable neurodegenerative conditions such as Alzheimer’s disease. 

For over a decade, Biogen has been committed to advancing ALS research to provide a deeper understanding of all forms of this devastating disease, which currently impacts an estimated 352,000 people worldwide. 

Biogen acquired Reata Pharmaceuticals in September 2023, and we are proud to build on the outstanding work Reata has done to launch the first and only U.S. Food and Drug Administration (FDA) approved treatment for FA in adults and adolescents aged 16 years and older. Biogen will leverage our rare disease expertise and capabilities to help bring this treatment to more patients living with this devastating disease.

Through our acquisition of Human Immunology Biosciences (HI-Bio) in July 2024, Biogen officially entered the nephrology space with a portfolio of investigational drugs that target immune-mediated diseases with serious unmet need. Biogen plans to leverage our expertise in immunology, clinical development, and commercialization capabilities to bring these potential new options to patients with these conditions.

As part of our long-standing efforts in neuroimmunology, we are utilizing our deep expertise in multiple sclerosis, our knowledge of immunological pathways, and our scientific and development synergies to positively impact the lives of people living with serious autoimmune diseases such as lupus.

Biogen has pioneered the development of multiple sclerosis treatments for more than 25 years. We continue to innovate to advance MS treatment and improve outcomes for patients. Our research is focused on potentially transformative therapies, including the potential repair of the damage caused by MS. Our ongoing research into neurodegeneration and nerve repair will help produce new therapeutic solutions that may bring us closer to a cure for MS. 

We are fearless in advancing the treatment of depression to transform the lives of those living with or impacted by this diagnosis. It is estimated that fewer than one-third of people living with depression receive adequate treatment and one in two women with postpartum depression are never diagnosed.

Biogen is dedicated to enhancing the lives of those with SMA and their families through ongoing research, removing barriers to access and providing support programs. In December 2017, Biogen launched a collaboration with Ionis to identify new therapeutic options — specifically, new antisense oligonucleotide (ASO) candidates, which are designed to treat SMA — for individuals afflicted with the debilitating disease.